FROM PROPHYLAXIS TO THERAPEUTICS: AN INTEGRATIVE REVIEW OF NANOTECHNOLOGICAL AND IMMUNOLOGICAL INNOVATIONS IN HPV MANAGEMENT
DOI:
https://doi.org/10.56161/reac.v2i1.59Keywords:
Human Papillomavirus Viruses, Papillomavirus Vaccines, Nanotechnology, Immunotherapy, Health Sciences, Technology and Innovation ManagementAbstract
Objective: To analyze the scientific evidence on nanotechnological and immunological innovations applied to the management of Human Papillomavirus (HPV), with emphasis on the development of therapeutic vaccines, nanostructured drug delivery systems, and diagnostic support technologies. Methods: An integrative literature review was conducted using the MEDLINE/PubMed, LILACS, and BDENF databases. The descriptors Papillomaviridae, Papillomavirus Vaccines, Nanotechnology, Drug Delivery Systems, and Immunotherapy were combined using the Boolean operators AND and OR. Studies published between 2016 and 2026 in English, Portuguese, and Spanish addressing nanotechnological and immunological strategies for HPV management were included. After the identification, screening, and eligibility phases, 11 studies composed the final sample. Results: The evidence was organized into three thematic axes: nanotechnological advances in HPV management, immunological innovations and therapeutic vaccine development, and molecular biotechnology associated with artificial intelligence. The findings demonstrated that nanostructured systems improve the controlled delivery of immunobiological agents and therapeutic compounds, while therapeutic vaccines targeting the viral oncoproteins E6 and E7 enhance cellular immune responses against infected cells. Furthermore, artificial intelligence tools and molecular biomarkers increase the accuracy of cervical cancer screening and early diagnosis, contributing to more personalized clinical decision-making. Conclusion: The emerging technologies identified in this review have substantial potential to transform the management of persistent HPV infections by enabling more precise, conservative, and individualized diagnostic and therapeutic approaches. Although the findings are promising, their widespread implementation in clinical practice depends on further multicenter clinical trials, regulatory validation, and cost-effectiveness analyses to support their safe and equitable incorporation into healthcare systems and strengthen cervical cancer prevention and control strategies.
References
Almeida, A. M., Costa, D., Simões, A. R., Queiroz, J. A., Sousa, F., & Sousa, Â. (2020). Enhancement of a biotechnological platform for the purification and delivery of a human papillomavirus supercoiled plasmid DNA vaccine. New Biotechnology, 59, 1–9. https://doi.org/10.1016/j.nbt.2020.04.003
Alouini, S., & Pichon, C. (2024). Therapeutic vaccines for HPV-associated cervical malignancies: A systematic review. Vaccines, 12(4), Article 428. https://doi.org/10.3390/vaccines12040428.
Arbyn, M., Weiderpass, E., Bruni, L., et al. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6
Aswathy, R., & Sumathi, S. (2025). The evolving landscape of cervical cancer: Breakthroughs in screening and therapy through integrating biotechnology and artificial intelligence. Molecular Biotechnology, 67(3), 925–941. https://doi.org/10.1007/s12033-024-01124-7
Bina, F., Bani, F., Khalilzadeh, B., Gheit, T., & Karimi, A. (2025). Advancements in fluorescent nanobiosensors for HPV detection: From integrating nanomaterials to DNA nanotechnology. International Journal of Biological Macromolecules, 311(Pt. 1), 143619. https://doi.org/10.1016/j.ijbiomac.2025.143619
Brasil. Ministério da Saúde. (2025). Portaria Conjunta SAES/SECTICS/MS nº 13, de 2025. Aprova as Diretrizes Brasileiras para o Rastreamento do Câncer do Colo do Útero: Parte I – Rastreamento Organizado por DNA-HPV na Atenção Primária à Saúde. Diário Oficial da União.
Brito, B. J. S., Brito, M. S., & Souza, A. M. (2024). Cobertura e efeitos da imunização contra o HPV pelo mundo: uma revisão de literatura. Brazilian Journal of Implantology and Health Sciences, 6(12), 2583-2589.
Bruni, L., Saura-Lázaro, A., Montoliu, A., et al. (2022). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive Medicine, 144, 106399. https://doi.org/10.1016/j.ypmed.2020.106399
Cardial, M. F. T., Roteli-Martins, C. M., Naud, P., & Fridman, F. Z. (2019). Papilomavírus humano (HPV). Feminina, 47(2), 94–100.
Cianciarullo, A. M., Vicente, P. I., Sakauchi, D., & Sasaki, É. A. K. (2022). Desenvolvimento de vacinas profiláticas e terapêuticas para HPV. Editora CRV.
Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019). Cervical cancer. The Lancet, 393(10167), 169–182. https://doi.org/10.1016/S0140-6736(18)32470-X
Gohar, A., Ali, A. A., Elkhatib, W. F., El-Sayyad, G. S., Elfadil, D., & Noreddin, A. M. (2022). Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology. Microbial Pathogenesis, 171, 105747. https://doi.org/10.1016/j.micpath.2022.105747
He, Z., Zheng, X., Liu, R., Zhao, K., Mao, D., Zhang, L., Wan, R., Zhang, H., & Wang, X. (2025). Recent advances in HPV detection: From traditional methods to nanotechnology and the application of quantum dots. International Journal of Nanomedicine, 20, 6333–6356. https://doi.org/10.2147/IJN.S524518
Hegde, Y. M., Theivendren, P., Srinivas, G., Palanivel, M., Shanmugam, N., Kunjiappan, S., Vellaichamy, S., Gopal, M., & Dharmalingam, S. R. (2023). A recent advancement in nanotechnology approaches for the treatment of cervical cancer. Anti-Cancer Agents in Medicinal Chemistry, 23(1), 37–59. https://doi.org/10.2174/1871520622666220513160706
Junior, C. R. B., de Paula-Júnior, W., de Aquino, M. V. L. R., Martins, T. A., Sakamoto, J. F., da Silva, A. G. G., ... & Guimarães, T. A. (2024). Barreiras ao cumprimento de metas de rastreio de Câncer de Colo Uterino no Brasil. Brazilian Journal of Implantology and Health Sciences, 6(6), 1662-1676.
Lopes-Nunes, J., Oliveira, P. A., & Cruz, C. (2024). Nanotherapy for human papillomavirus-associated cancers: breakthroughs and challenges. Trends in Pharmacological Sciences, 45(9), 781-797.
Malagon, T., Franco, E. L., Tejada, R., & Vaccarella, S. (2024). Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nature Reviews Clinical Oncology, 21(7), 522-538.
Mendes, K. D. S., Silveira, R. C. C. P., & Galvão, C. M. (2008). Revisão integrativa: Método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto – Enfermagem, 17(4), 758–764. https://doi.org/10.1590/S0104-07072008000400018
Negahdaripour, M., Nezafat, N., Heidari, R., Erfani, N., Hajighahramani, N., Ghoshoon, M. B., Shoolian, E., Rahbar, M. R., Najafipour, S., Dehshahri, A., Morowvat, M. H., & Ghasemi, Y. (2020). Production and preliminary in vivo evaluations of a novel in silico-designed L2-based potential HPV vaccine. Current Pharmaceutical Biotechnology, 21(4), 316–324. https://doi.org/10.2174/1389201020666191114104850
Sabah, S. N., Gazi, M. A., Sthity, R. A., Husain, A. B., Quyyum, S. A., Rahman, M., & Islam, M. R. (2018). Designing of epitope-focused vaccine by targeting E6 and E7 conserved protein sequences: An immuno-informatics approach in Human Papillomavirus 58 isolates. Interdisciplinary Sciences: Computational Life Sciences, 10(2), 251–260. https://doi.org/10.1007/s12539-016-0184-5
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nature Reviews Cancer, 21(6), 360–378. https://doi.org/10.1038/s41568-021-00346-0
Sharma, U., Shekhar, H., Sharma, B., Sahu, A., Haque, S., Mathkor, D. M., & Ahmad, F. (2025). Emerging nanotherapeutics for HPV-associated cancers: current advances, challenges, and future directions. Discover oncology, 16(1), 1653.
Shamsipur, M., Nasirian, V., Mansouri, K., Barati, A., Veisi-Raygani, A., & Kashanian, S. (2017). A highly sensitive quantum dots-DNA nanobiosensor based on fluorescence resonance energy transfer for rapid detection of nanomolar amounts of human papillomavirus 18. Journal of Pharmaceutical and Biomedical Analysis, 136, 140–147. https://doi.org/10.1016/j.jpba.2017.01.002
Skeate, J. G., Da Silva, D. M., Chavez-Juan, E., Anand, S., Nuccitelli, R., & Kast, W. M. (2018). Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS ONE, 13(1), e0191311. https://doi.org/10.1371/journal.pone.0191311
World Health Organization. (2020). Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization. https://www.who.int/publications/i/item/9789240014107
World Health Organization. (2022). Human papillomavirus vaccines: WHO position paper, December 2022. Weekly Epidemiological Record, 97(50), 645–672. https://www.who.int/publications/i/item/who-wer9750-645-672
World Health Organization. (2024). WHO preferred product characteristics for therapeutic HPV vaccines. World Health Organization. https://www.who.int/publications/i/item/9789240092174
Yousaf, S., Shehzadi, A., Ahmad, M., Asrar, A., Ahmed, I., Iqbal, H. M. N., & Bule, M. H. (2024). Recent advances in HPV biotechnology: Understanding host-virus interactions and cancer progression. International Journal of Surgery, 110(12), 8025–8036. https://doi.org/10.1097/JS9.0000000000002117
Zhou, X., Lian, H., Li, H., Fan, M., Xu, W., & Jin, Y. (2022). Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy. Frontiers in Pharmacology, 13
, 1065793.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista Brasileira de Atualizações em Ciências e Saúde (REAC)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.